Kornimate/medical-research-clean huggingface dataset:
uterine balloon treatment for heavy period bleeding.

Conditions: Menorrhagia

Summary: the purpose of this research is to determine the proportion of women who achieve permanent cessation of bleeding after uterine balloon therapy (ubt) for the treatment of heavy uterine bleeding.

this study was also designed to determine the effect of a post procedure curettage on bleeding patterns and post-operative discharge and pain.

Eligibility criteria:
inclusion criteria: * female at least 30 years of age who is premenopausal and for whom childbearing is complete. * excessive menstrual bleeding documented by a diary score of at least 150. * have documented 3 months failed medical therapy or either a) contraindicated for or b) refused medical therapy. * have an anatomically normal uterine cavity sounding at least 4cm, but not greater than 12cm. * have a normal pap smear and no unexplained abnormal pap smears within 1 year of the procedure. * agree not to switch from hormonal to non-hormonal contraception or vice versa during or just prior to the study. * agree to use reliable contraception throughout the study. * freely agree to participate in the study, including all study related procedures and evaluations, and document this agreement by signing informed consent documentation. exclusion criteria: * active pelvic inflammatory disease (pid) or recurrent chronic pid. * active genital or urinary tract infection at the time of the procedure. * history of malignancy of the reproductive system within 5 years of the procedure or have ever had malignancy of the endometrium. * endometrial neoplasia, determined by endometrial biopsy taken within 6 months of procedure. * cavity distorting submucous myoma(s) determined by preoperative hysterogram, hysteroscopy, or transvaginal sonography within 6 months of the procedure. * previous endometrial ablation procedure. * previous uterine surgeries (such as full thickness myomectomy, subserosal myomectomy, uterine reconstruction, or any surgery in which thinning of the uterine musculature could occur) except for low transverse caesarean section. * pregnant or desirous of future pregnancy. * taken endometrial suppression medication, except for oral contraceptives, within 3 months of the procedure. * concurrent open or laparoscopic surgery.
efficacy of the use of risk scores in reducing important clinical outcomes in hospitalized medical ill patients

Conditions: Prevention of Venous Thromboembolism

Summary: fadoi (italian scientific society of hospital internal medicine) has planned to promote a multicenter cluster-randomized controlled clinical study in order to evaluate the effects of a systematic assessment of patients by using the padua prediction score and the improve bleeding score vs clinical judgement on the use of antithrombotic prophylaxis and clinical outcomes (thromboembolic and hemorrhagic events).

the most recent guidelines suggest the use of prophylaxis in patients with a high thromboembolic risk, while taking into account the risk of bleeding. it is known that patients admitted for acute pathology have an eight-fold higher incidence of thromboembolic events than the general population. the padua prediction score (pps) is currently considered the best score available for the evaluation of thromboembolic risk in hospitalized patients, while the improve score was developed and validated for the assessment of bleeding risk in the same population of hospitalized patients. in a recent study, data from the real world showed us how many of the patients admitted in internal medicine were at high thrombotic risk according to pps and almost 90% of these were simultaneously at low hemorrhagic risk according to the improve score: in these patients pharmacological prophylaxis could therefore be prescribed during a safe stay. until now only a small prospective monocentric quasi-randomized study has shown that the use of systematic pps reduces the incidence of thromboembolic events (symptomatic and non-symptomatic) upon discharge, compared to clinical judgment alone. for these reasons, fadoi foundation has promoted a multicenter controlled randomized cluster study in a real-life context among patients admitted to medical area departments. the aim of the study will be to analyze the effects of a systematic evaluation of patients (in centers that do not require the use of any score for the evaluation of thromboembolic risk), using the padua prediction score (pps) and the improve bleeding score vs only clinical judgment for the use of antithrombotic prophylaxis and clinical outcomes (thromboembolic and haemorrhagic events). the main objective of the study is therefore to evaluate the effectiveness of a systematic evaluation of the thromboembolic and hemorrhagic risk in reducing the number of major complications in patients admitted to internal medicine, at a 90-day follow-up after hospital discharge.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. hospitalized for any cause in internal medicine 3. signature of informed consent exclusion criteria: 1. expected hospital stay \< 48 h 2. any indication for anticoagulant therapy 3. life expectancy \< 90 days
developing and testing motherly app: a smartphone application to promote mothers' mental health

Conditions: Maternal Depression

Summary: the investigators plan to develop and test motherly, a smartphone app to promote maternal mental health and child development. the motherly app is visually appealing aimed at engaging the user with a minimalistic layout. the app will offer a gamified experience ideal for engaging youth in behaviors that can promote mental health, such as stimulating pleasure, productivity, and physical activities, connecting with peers, and eating healthy food. pregnant women aged 16-34 living in brazil will participate in the clinical trial to test the efficacy of the intervention.


Eligibility criteria:
inclusion criteria: * literate women in the first or second trimester of pregnancy * living in brazil * owning a functional smartphone for personal use with android or ios operational system exclusion criteria: * high-risk pregnancy
ct abnormalities evocative of lung infection are associated with lower 18f-fdg uptake in confirmed covid-19 patients

Conditions: Presence of COVID-19 Compatible CT Abnormalities

Summary: ct signs that are evocative of lung covid-19 infections have been extensively described, whereas 18f-fdg-pet signs have not. our current study aimed to identify specific covid-19 18f-fdg-pet signs in patients that were (i) suspected to have a lung infection based on 18f-fdg-pet/ct recorded during the covid-19 outbreak and (ii) whose covid-19 diagnosis was definitely established or excluded by appropriate viral testing.


Eligibility criteria:
inclusion criteria: * patient coming to nuclear medicine for 18f-flurodesoxyglucose (fdg) positron emission tomography computed tomography (pet-ct) with suspicion of lung involvement * patient affiliated to a social security scheme or equivalent * adult patient having been informed of the study exclusion criteria: * patient with a negative covid 19 test

Keywords: covid19 18f fdg pet lung infection ct seriological tests
effectiveness of rice germ supplementation on body composition, metabolic parameters, satiating capacity and amino acid profiles in obese postmenopausal women

Conditions: Obesity

Summary: rice germ (rg) may be a safe and effective dietary supplement for obesity in menopause, considering its high protein content and considerable amounts of essential amino acids, good fatty acids, and fiber. this pilot randomized, blinded, parallel group, placebo-controlled pilot trial investigated the effectiveness of four weeks of rg supplementation (25 g twice a day) on body composition, measured by dual energy x-ray absorptiometry (dxa), as primary outcome, and metabolic parameters, amino acid profiles and satiating capacity, as secondary outcomes, in obese postmenopausal women following a tailored hypocaloric diet (25-30% less than daily energy requirements). twenty-seven women were randomly assigned to the supplemented group (14) or placebo group (13). there was a significant interaction between time and group for body mass index (bmi) (p\<0.0001), waist (p=0.002), and hip circumference (p=0.01), total protein (0.008), albumin (0.005), homeostasis model assessment index (p=0.04), glycine (p=0.002), glutamine (p=0.004), and histidine (p=0.007). haber's means over time showed a clearly greater feeling of satiety for the supplemented compared to the placebo group. these findings indicate that rg supplementation in addition to a tailored diet counterbalanced the metabolic changes typical of menopause, with improvements in bmi, body composition, insulin resistance, amino acid profiles and satiety.


Eligibility criteria:
inclusion criteria: * obesity (bmi 30-40 kg/m2) * age 50-65 * menopause * sedentary women and non-smoking, * women who did not drink more than six glasses (one glass: 125 ml) of wine a week and did not drink hard liquor (alcohol content at least 20% alcohol by volume) * women who agreed not to take part in any other weight loss program exclusion criteria: * evidence of heart, kidney or liver disease * women who met the diagnostic and statistical manual-iv (dsm-v) criteria for a current diagnosis of major depressive disorder * taking any medications for weight loss * control of cholesterol and triglycerides for anti-inflammatory purposes * pregnancy * lactating * type 1 diabetes mellitus, irritable bowel disease, celiac disease, chronic pancreatitis * antibiotic use in the last three months * probiotic/prebiotic treatment in the last four weeks.

Keywords: rice germ body composition amino acids
the safety and effectiveness of indinavir plus ritonavir plus two nrtis in hiv-infected patients who need early intervention treatment

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 nrtis to hiv-infected patients who need early intervention treatment.

patients receive indinavir bid plus ritonavir bid, plus 2 nrtis bid (2 new nrtis or 1 new nrti and 1 nrti without evidence of resistance). cd4 cell counts and plasma viral rna are measured every 4 weeks for the duration of the study. physical examination and laboratory tests of blood and urine are performed every 4 weeks for the duration of the study. chest x-ray and 12-lead ecg are done prestudy.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * are 18 years of age or older. * have a cd4 cell count of at least 50 cells/mm3. * have a viral load (level of hiv in the blood) of at least 400 copies/ml but no more than 20,000 copies/ml. * have had an initial response to protease inhibitor therapy with a viral load of less than 400 copies/ml in two consecutive tests at least 1 week apart. * have been on anti-hiv (antiretroviral) treatment including indinavir or nelfinavir for at least 16 weeks. * have had virologic failure (two consecutive viral loads that were greater than or equal to 400 copies/ml and less than or equal to 20,000 copies/ml at least 1 week apart) that is not due to another infection, vaccination, or a temporary stop in treatment. * are naive to at least one of the selected nrtis.

Keywords: hiv-1 drug therapy, combination hiv protease inhibitors ritonavir indinavir reverse transcriptase inhibitors anti-hiv agents viral load nelfinavir
dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer

Conditions: Gastric Adenocarcinoma

Summary: this is an open-label, phase ii study to evaluate the efficacy and safety of biweekly docetaxel and degramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.

primary endpoint: overall response rate secondary endpoint: time to progression, overall survival, safety data

Eligibility criteria:
inclusion criteria: * signed written informed consent * patients with histologically or cytologically confirmed unresectable gastric adenocarcinoma whose ecog performance status are 0-2 * presence of measurable disease by radiographic study (including ct or mri scan, or chest x-ray) or physical examination * at least 3 weeks since last major surgery * at least 12 months since last adjuvant chemotherapy * at least 6 weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is not expected * patients who have received palliative radiotherapy must have recovered from any reversible toxic effects e.g. nausea and vomiting caused by radiation of fields * patients with reproductive potential must use effective bc; * required screening laboratory criteria: hemoglobin 90g/l wbc 3.5 x 109/l neutrophils 1.5 x 109/l platelets 100 x 109/l creatinine 133 umol/l and creatinine clearance 60 ml/min * a probable life expectancy of at least 6 months; exclusion criteria: * brain metastases * female of childbearing potential, pregnancy test is positive * concomitant malignancies or previous malignancies other than gastric cancer within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or low grade prostate cancer * active infection * concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk * sexually active patients refusing to practice adequate contraception; patients with conditions which might affect absorption of an oral drug (for example intermittent obstruction) unless discussed and agreed with principal investigator * history of grade 3 or 4 toxicity to fluoropyrimidines

Keywords: docetaxel fluorouracil first line therapy gastric cancer
a clinical trial of safety and efficacy of fasudil in subjects with amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: this study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (als).

this is an open labeled, single center clinical study with placebo of historical researches as control. 10 patients will be enrolled in the study. the basic treatment is riluzole, 50mg twice a day. for the procedure, patients will take fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later, patients will repeat the fasudil treatment. all the patients will be followed up for 6 months. the primary outcome was the decline rate of alsfrs-r. the secondary outcomes are the survival time, endpoint time(death, tracheotomy and continuous ventilator-dependent), forced vital capacity (fvc), the short form health survey (sf-36), evaluation of cognitive function (verbal fluency and frontal behavioral inventory scale) and safety.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of laboratory-supported probable, probable, or definite als * age: 18-70 years * disease duration: 3-36 months * forced vital capacity: at least 60% of predicted * alsfrs-r: at least 30, respiratory items: at least 10 * decline of alsfrs-r in the last 3 months before enrollment: 1-8 * must take riluzole, on a stable dose for at least 30 days prior to baseline visit with no serious side effects. they must continue the riluzole treatment for at least 6 months after enrollment. * patients of childbearing potential must be using an effective method of birth control * willing and able to give informed consent exclusion criteria: * familial als * pregnant or nursing women * patients after tracheotomy or continuous ventilator-dependent (time with non-invasive ventilator more than 22 hours per day for 7 consecutive days.) * after percutaneous endoscopic gastrostomy * alanine transaminase (alt) or aspartate transaminase (ast): at least 3 times the upper limit of normal * abnormal creatinine or urea nitrogen * severe cardiac disease, pulmonary disease, hematic disease, autoimmune disease, mental disease, dementia and substance abuse * history of malignancy * history of intracranial hemorrhage * history of severe bleeding of digestive tract, lungs, nose and skin * allergic to fasudil * participating in other clinical studies or using other investigational drugs at present
biomarkers for the early identification of sepsis in the emergency department

Conditions: Sepsis

Summary: monocentric prospective study on consecutive patients attending the emergency department and suspected to have sepsis. blood sampling for the measurement of a panel of biomarkers of interest in sepsis.

the management of patients admitted to the emergency department (ed) requires investigative biological parameters that help clinicians to make the right diagnosis. sepsis concerns patients with infection associated with a systemic inflammatory response. while this inflammatory profile is observed in many clinical situations in the ed, the challenge is to characterize in these patients suspected of sepsis those who have a real infection. currently, no individual biomarker of sepsis is sufficiently discriminant. the objective of this study is to measure in patients suspected of sepsis in the emergency department, a combination of biomarkers (covering several distinct pathophysiological pathways) that could provide high specificity and sensitivity for the diagnostic and prognostic. the originality of this study is that compared with patients admitted to intensive care units, patients investigated for suspected sepsis in the ed are seen earlier in their medical history and usually before any therapeutic intervention (intravenous fluids, antibiotics, catecholamines) interfering with several biomarkers of interest.

Eligibility criteria:
inclusion criteria: * patient attending the ed and suspected to have sepsis by the emergency physician after clinical exam exclusion criteria: * patient minor under 18-year * pregnancy * anticipated no follow-up possible (homeless...) * refusal to participate * patient under curators, prisoner

Keywords: sepsis biomarker prognostic emergency department diagnosis
a comparative study of adding ipratropium to salbutamol for the treatment of asthma attack in children

Conditions: Asthma Exacerbation; Children

Summary: the goal of this clinical trial was to determine if adding ipratropium bromide to salbutamol improves asthma treatment in children. the main question this study aimed to answer was: does combining ipratropium with salbutamol improve asthma symptoms more effectively than salbutamol alone? researchers compared salbutamol alone to a combination of salbutamol and ipratropium in children with acute asthma. participants: (i) received either salbutamol alone or salbutamol with ipratropium via nebulization for 4 hours (ii) had their asthma symptoms assessed before and after treatment (iii) were discharged with continued treatment and counseling if stable this study was conducted in the department of pediatric medicine, children's hospital multan, over six months. a total of 60 children with acute asthma were included.

children presenting with asthma exacerbation were assessed for eligibility. eligible participants had their baseline characteristics recorded including age, gender, history of parental asthma, duration of asthma diagnosis, use of asthma controllers (inhaled corticosteroids, long acting beta agonist (laba), montelukast) \& baseline pulmonary asthma score. through lottery method using sequentially numbered sealed opaque envelopes children were assigned to group a and group b treatments. at the end of 4-hours of therapy, pulmonary asthma score was re-assessed by pediatrician not aware of treatment assigned. once stabilized, the children were discharged on regular nebulization therapy with controller medication after proper counseling.

Eligibility criteria:
inclusion criteria: * children with acute asthma exacerbation (presenting with wheeze, labored breathing with ronchi audible on auscultation) * within 12 hours of symptom onset exclusion criteria: * children with known pulmonary and/or cardiac congenital malformations * bronchopulmonary dysplasia * cystic fibrosis * post infectious bronchiolitis obliterans * altered mental status on presentation with imminent respiratory failure (pulmonary asthma score ≥ 10, cases needing picu care)

Keywords: asthma salbutamol ipratropium bromide pulmonary asthma score
performance of class i composite restorations after cavity finishing by air abrasion versus diamond stone

Conditions: Abrasion, Dental; Class I Dental Caries

Summary: the aim of the study is to reveal the performance of the resin composite restorations after finishing the cavity walls and margins using bioactive glass air abrasion particles in comparison to the routine finishing with the finishing diamond stone according to the fdi criteria for post operative sensitivity, marginal adaptation, marginal discoloration, secondary caries, and retention.

intraoral air abrasion is the process of altering the surface of the tooth structure through the use of abrasive particles propelled by compressed air or other gasses. the use of intraoral air abrasion has become practical with devices that simultaneously output abrasive particles and water to control the spread of the particles. there are different types of abrasive particles maybe used depending on the clinical application for which the intraoral air abrasion is being performed. intraoral air abrasion may also be used as a tool for dental prophylaxis, often called air polishing. different particles could be incorporated into air abrasion devices according to the intended use of them, such as aluminum oxide (alumina), calcium sodium phosphosilicate (biactive glass) and sodium bicarbonate. to obtain maximum cutting efficiency, the particle should be hard enough to indent the substrate it abrades, and irregular in shape with a sharp cutting edge. round and smooth particles possess poor abrasive properties, so it may be used for polishing needs "air- polishing". increased air pressure provided an increased number and velocity of the particles. abrading power must be proportional to kinetic energy of the particles, which is the function of mass and velocity of the particle. the cutting efficiency of air abrasion depends on several criteria, such as: size, shape, hardness, density of the particles and air pressure. aluminum oxide (alumina) are the most abrasive type of particles used. they are irregular in shape with different particle sizes. intraoral sandblasting with alumina particles (al2o3) was first described in 1945 by black. initially, it was reported that the bond strength to the tooth surface improved, also confirmed by recent investigations, and some authors adopted its use in clinical procedures even after preparing the cavity with rotating instrument. a bioactive glass abrasive, is also commercially available but indicated for the purpose of tooth polishing. some work has also showed potential for it to have selective cutting properties. however, its cutting time can take 2-3 times longer than alumina, making it clinically indicated for cavity finishing and not cutting.

Eligibility criteria:
inclusion criteria: * good oral hygiene (plaque index score 0 or 1). * absence of abnormal occlusion habits (e.g. bruxism, nail biting, tooth clenching and mouth breathing). * patients approving to participate in the study. exclusion criteria: * patients with known allergic or adverse reaction to the tested materials. * systematic disease that may affect participation. * xerostomic patients.